Citations

Abstract Introduction Cardiac arrest (CA) is the sudden cessation of cardiac activity, leading to haemodynamic collapse and high mortality. Advanced life support (ALS) standardises resuscitation, but the post-return of spontaneous circulation (ROSC) period remains turbulent and poorly understood. Up to 50% of patients who achieve ROSC struggle to maintain spontaneous circulation, leading to re-arrest, typically within minutes. Post-cardiac arrest syndrome (PCAS), involving brain injury and ischaemia-reperfusion injury, plays a key role in re-arrest. Pressure-volume loop (PVL) analysis offers insight into load-independent cardiac biomechanics in the post-ROSC period. The aim of this study is to explore the feasibility of PVL analysis in a swine model of CA. Methods This swine study utilised a ventricular fibrillation (VF) cardiac arrest model in combination with PVL analysis. The experiment included four phases: animal preparation, VF induction, resuscitation, and post-ROSC care. Yorkshire swine (45-70 kg) were sedated, anaesthetised, and VF was induced via an endocavitary electrode attached to a battery. After that, the animals were divided into 3-minute and 6-minute arrest groups before commencing ALS. Standard ALS protocols were followed, including CPR, defibrillation, and drug administration. If ROSC was obtained, animals underwent a 3-hour critical care period. Cardiac indices were compared between baseline and end-of-study values. Results Eight adult Yorkshire swine were enrolled in the study, with a mean weight of 50.2 ± 2.9 kg. VF induction was successfully achieved, and PVL data were collected in all animals except one, establishing a successful porcine VF CA model. In the resuscitation phase, all animals in the 3-minute group achieved ROSC, as opposed to one in the 6-minute group. Post-ROSC metabolic changes included acidaemia, elevated lactate and potassium, partially resolving by study end. Right ventricle PVL data were unreliable, while left ventricle PVL was reliable in 3 of 5 ROSC animals. Preload-recruitable stroke work (PRSW) data were found to be more reliable than the End-Diastolic Pressure-Volume Relationship (ESPVR), with a significant increase in LV PRSW of 34 ± 12% observed post-ROSC in all surviving animals (p<0.001). Discussion This study demonstrates the feasibility of applying PVL analysis to a post-ROSC swine model of cardiac arrest (CA). As expected, warm ischaemic time predicted ROSC, but PVL analysis offered valuable insights into load-independent parameters. While data quality issues hindered ESPVR analysis, PRSW was successfully evaluated, revealing a significant increase post-ROSC, highlighting its potential to guide the development of future therapeutic targets for post-ROSC interventions. The small sample size and technical challenges limited the scope of conclusions, emphasising the need for larger studies.Kaplan-Meier Curve and cycles to ROSC (A) LV PVL, (B) PRSW Pre and Post-ROSC

Abstract Background Ankle-brachial indices (ABI) predict mortality and major cardiovascular events (MACE); however, they are unable to assess the severity of peripheral artery disease in patients with non-compressible vessels. Toe brachial indices (TBI) are less affected by non-compressibility and could be good predictors of cardiovascular morbidity and mortality. Purpose To evaluate the predictive value of TBI for MACE and all-cause mortality in a large population. Methods The initial ABIs and TBIs of all patients referred to a noninvasive vascular laboratory were obtained. We categorized patients based on the worse TBI from either leg, and each patient was classified as normal (>0.8), borderline (0.8-0.61), mild-moderate PAD (0.6 - 0.21) and severe PAD (≤0.2). MACE occurring after the study were identified using ICD9/10 and procedural CPT codes and included myocardial infarction, coronary revascularization, or stroke. Survival analysis was performed using the Kaplan-Meier method with log-rank test to compare survival curves between groups. Results Of 13551 patients, we excluded 643 (5%) in whom TBI could not be obtained. Patient characteristics can be found in Table 1. There were 4,924 MACE and 3,125 deaths during the median follow up time of 8.39 years (Table1). There was a significant difference of MACE incidence (p <0.001) and mortality (p<0.001) by TBI categories, and the curves separate before the 1-year mark (Figure 1A and B). Conclusion TBI is a good predictor of MACE and all-cause mortality in the short and long term and can be obtained in 95% of patients.

Abstract Background Ventricular fibrillation (VF) is a leading cause of sudden cardiac death worldwide. Defibrillation via direct current shocks is effective but associated with significant pain and morbidity, prompting the need for alternative approaches. Reversible electroporation of cardiac tissue with pulsed electric fields (PEF) may be an effective means of terminating VF. Purpose To assess the feasibility of PEF delivery for terminating VF. Methods 5 acute swine models were used. Mechanical circulatory support with peripheral veno-arterial extracorporeal membrane oxygenation +/- percutaneous left ventricular assist device (Impella 5.5 L) was implemented and titrated to a mean arterial pressure ≥65 mmHg. Decapolar catheters were introduced into the endocardial right and/or left ventricle as well as epicardium. VF was induced with R on T shocks or rapid ventricular pacing. PEF was delivered with the endocardial catheter as the cathode and epicardial catheter as the anode; monophasic pulses (5-10) at 3000V, 100µs, and 200ms inter-pulse intervals were used. If VF persisted post-PEF, catheters were repositioned into regions of intact voltages for repeat delivery. Results 10 VF episodes were induced, 7 of which were successfully terminated with PEF delivery (70.0%). The median number of attempts to achieve VF termination was 2 (range 1-5). The post-VF rhythm was complete heart block with ventricular asystole in all successful defibrillation attempts, with no recovery after 30 minutes of observation. Significant muscle stimulation was seen with the utilized PEF parameters and catheter configurations. Conclusion Termination of VF using PEF – pulsed field defibrillation – is possible. However, further study is required to optimize delivery parameters/configurations to improve effectiveness and avoid muscle stimulation as well as conduction abnormalities.

Abstract Background Alcohol consumption and its relationship with cardiovascular disease (CVD) remains controversial. Observational studies have reported J-shaped associations suggesting cardioprotective effects of moderate drinking, while other observational and Mendelian Randomization studies have found dose-response harm. Biases such as abstainer misclassification, sick quitter effects, and residual confounding may obscure true associations. This study aimed to reassess alcohol’s impact on CVD using novel methods to minimize bias. Purpose We evaluated the relationship between alcohol and subclinical (coronary artery calcium [CAC]) and clinical (myocardial infarction [MI], stroke, cardiovascular death, major adverse cardiovascular events [MACE], and heart failure) outcomes in the Multi-Ethnic Study of Atherosclerosis (MESA). We compared conventional models with those using (1) occasional drinkers as the reference group instead of lifetime abstainers and (2) intention-to-treat (ITT) reallocation of former drinkers based on past drinking patterns. Methods MESA is a prospective cohort study of 6,814 participants aged 45-84 years without baseline CVD. Alcohol use was classified as lifetime abstainer, former drinker, or current drinker (occasional [≤1 drink/week], light [2-7 drinks/week], moderate [8-14 drinks/week], heavy [>14 drinks/week]). We used multinomial logistic regression for CAC and Cox proportional hazards models for clinical outcomes across four models: (1) non-drinker reference, (2) lifetime abstainer reference, (3) occasional drinker reference, and (4) occasional drinker reference with ITT reallocation of former drinkers to their previous drinking levels. Results Increasing alcohol consumption correlated with a dose-response increase in CAC. Heavy drinking was consistently associated with severe CAC (>300). In fully adjusted models, light (OR: 1.23, 95% CI: 1.02-1.48), moderate (OR: 1.27, 95% CI: 1.04-1.55), and heavy drinking (OR: 1.42, 95% CI: 1.12-1.78) were associated with higher CAC scores compared to occasional drinkers. Traditional models replicated protective effects of moderate drinking for MI and cardiovascular mortality. However, these associations attenuated in adjusted models. Moderate drinking showed an attenuated, non-significant benefit for MI (HR: 0.64, 95% CI: 0.38-1.06) and cardiovascular mortality (HR: 0.81, 95% CI: 0.53-1.25) in fully adjusted models. Light drinking shifted from null to increased risk for MI (HR: 1.46, 95% CI: 1.11-1.92), stroke (HR: 1.54, 95% CI: 1.17-2.03), MACE (HR: 1.33, 95% CI: 1.12-1.57), and heart failure (HR: 1.42, 95% CI: 1.10-1.84). Conclusion Adjusting for abstainer and sick quitter biases altered the observed relationship between alcohol and CVD, showing increased harm with light drinking, attenuated protective effects of moderate drinking, and a dose-response relationship for CAC in bias-adjusted models. These findings illustrate the importance of methodology in alcohol-CVD relationships.

Abstract Background Implantable cardioverter-defibrillator (ICD) is a well-established therapeutic option associated with decreased mortality in patients with ischemic and non-ischemic cardiomyopathies. However, the indications for patients with chronic Chagas cardiomyopathy (CCC) are not well established since these patients were underrepresented in the trials validating ICD use. Purpose This systematic review and single-arm meta-analysis aims to synthetize the available evidence in the literature on the role and outcomes of ICD in CCC. Methods A systematic search of PubMed, Web of Science, Cochrane, and LILACS registries was performed following PRISMA guidelines. Studies evaluating the response to ICD in CCC were included. There were no language restrictions. Data were collected and synthesized using a meta-analysis of proportions with Freeman-Tukey double-arcsine transformation as needed. Results We included 14 observational studies and 1 randomized clinical trial (RCT), comprising 1315 patients with CCC. Mean age at ICD implantation was 58.2 ± 11.8, 65% were male, and 77% received an ICD for secondary prevention. During a mean follow up of 37.3 ± 37.0 months, the all-cause death rate was 22% (95% CI 15 to 29%; Figure 1A), the cardiovascular death rate was 16% (95% CI 11 to 22%; Figure 1B), the sudden cardiac death rate was 3% (95% CI 2 to 5%), and the non-cardiovascular death rate was 7% (95% CI 2 to 5%). In addition, 55% (95% CI 43 to 67%; Figure 1C) of patients received ≥1 appropriate ICD therapy (shocks or antitachycardia pacing), 8% (95% CI 5 to 12%) received inappropriate ICD shocks, and 23% (95% CI 11 to 37%) experienced electrical storms. Conclusion Despite ICD, the mortality rate in patients with CCC remains unacceptably high, primarily driven by cardiovascular causes, with frequent appropriate ICD therapies and electrical storms. Further studies are needed to better delineate the benefits and risks of ICD therapy in patients with CCC.Figure 1

Abstract Background Short QT syndrome type 1 (SQT1) is a genetic channelopathy caused by gain-of-function variants in the KCNH2-encoded Kv11.1 potassium channel, responsible for the repolarising IKr current. These variants lead to pathologically shortened cardiac repolarisation and QT intervals on 12-lead ECG, predisposing patients to life-threatening ventricular arrhythmias and sudden cardiac death. Purpose To investigate the therapeutic efficacy of our KCNH2-specific suppression-replacement gene therapy (KCNH2-SupRep) in transgenic SQT1 rabbits generated by cardiac-specific overexpression of KCNH2-N588K. Methods KCNH2-SupRep was developed by combining a custom-designed KCNH2 shRNA with its corresponding shRNA-immune KCNH2 cDNA, packaged into a single AAV9 vector and delivered directly into the aortic root via a Swan Ganz catheter (1E10 vg/kg). Therapeutic efficacy was evaluated in vivo by 12-lead ECG recordings pre- and three weeks post-therapy, ex vivo by optical voltage mapping, and at the cellular level by patch-clamp, calcium imaging, and qPCR in ventricular cardiomyocytes (VCMs) isolated from adult transgenic SQT1 and wild-type (WT) rabbits. Results In vivo, KCNH2-SupRep normalized the heart-rate corrected QT interval (QTc) in transgenic SQT1 rabbits towards WT levels (baseline-SQT1: 153±4ms vs SupRep-SQT1: 167±5ms, p=0.0002; Fig. 1A), without adversely impacting repolarisation heterogeneity. No such QTc changes were observed in sham-treated SQT1 rabbits (sham-SQT1) (baseline-SQT1: 155±4ms vs sham-SQT1: 146±5ms, p=0.1422). Ex vivo, at a 2.5Hz stimulation frequency, KCNH2-SupRep therapeutically prolonged the APD90 in SupRep-SQT1 hearts (176±4ms) near WT levels (179±4ms), compared to untreated (UT)-SQT1 (154±4), and resolved the pathologically increased apicobasal APD90 heterogeneity observed in UT-SQT1 hearts, supporting an anti-arrhythmic effect of KCNH2-SupRep (Fig. 1B). At the cellular level, at a 1Hz stimulation frequency, KCNH2-SupRep prolonged the APD90 in VCMs isolated from SupRep-SQT1 rabbits (363±11ms) closer to WT levels (404±14ms) as compared to UT- (314±12ms) and sham-SQT1 (322±11ms; Fig. 1C). Moreover, KCNH2-SupRep restored the cellular surrogate of the electro-mechanical window (cEMW, Ca2+ transient duration – APD) and normalized IKr in nearly 50% of VCMs (Fig. 1D), in line with a 50-60% suppression of the mutant KCNH2 transcript. This partial therapeutic effect on IKr may explain the incomplete APD90 normalization in individual VCMs. Nonetheless, both in vivo and ex vivo, this partial therapeutic effect was sufficient to completely restore the electrical properties. Conclusion This proof-of-concept study is the first to demonstrate the efficacy of gene therapy in treating SQT1 in a medium-sized animal model. KCNH2-SupRep rescued the disease phenotype in vivo, ex vivo and at cellular levels in transgenic SQT1 rabbits.Therapeutic efficacy of KCNH2-SupRep

Abstract When using real-world data to construct an external comparator arm for a single-arm trial, there may be differences in how and when patients are assessed for disease between trial and real-world settings. Such differences can generate outcome measurement error when comparing time-to-event endpoints and lead to biased findings. Recent methods have been developed to mitigate measurement error bias in real-world endpoints; however, they rely on the existence of a validation sample, ie, data on a set of patients where both the “true” trial-like and “mis-measured” real-world measures are collected. We demonstrate how novel statistical methods can be leveraged as quantitative bias analyses (QBA) to contextualize real-world evidence findings when outcome measurement error is of concern, but validation samples are infeasible to collect. Quantitative bias analyses allow researchers to set plausible ranges for the amount of error when not directly measurable. We highlight how to conduct QBA with two recent methods, cumulative incidence curve correction and survival regression calibration, and illustrate how to generate plausible parameter values through simulation. We provide an illustrative QBA example in a cohort of real-world patients with newly diagnosed multiple myeloma and provide practical guidance to apply QBA for outcome measurement error and interpret results.

Abstract Background/Introduction Macrotroponin refers to high-molecular-weight troponin complexes bound to immunoglobulins, shown to cause persistently elevated troponin values often unrelated to myocardial injury. We hypothesized that its frequency might increase with age and differ between men and women, reflecting potential age-related cardiac changes and sex-specific risk profiles. Purpose To assess whether macrotroponin frequency varies across age groups and by sex within the upper sex-specific 90th percentile of troponin values in a healthy Danish reference population. Methods Among 1,307 participant samples with normal-range NT-proBNP, HbA1c, and eGFR ≥90 mL/min/1.73m2, 147 samples with troponin I within the upper levels of the sex-specific 90th percentile for the Siemens Atellica assay were further tested for macrotroponin I using Protein A/G immunoglobulin depletion and sucrose gradient ultracentrifugation. Samples were only deemed macrotroponin-positive by concordantly positive results. After excluding 29 samples with low troponin values due to analytical dilution constraints, 118 participants remained. Macrotroponin I frequency was compared across three age groups (<40, 40–60, and >60 years) and between sexes. Logistic regression was used to adjust for creatinine levels. Results Of 118 samples tested (48% females), macrotroponin I was present in 88 (75%), with similar frequencies in women (80%) and men (77%). Macrotroponin I frequency did not differ significantly across age groups (p=0.26) or between sexes (p>0.5) (Table 1, Figure 1). Logistic regression revealed no significant associations between macrotroponin I and age group, sex, or creatinine levels (all p > 0.5). Conclusion Macrotroponin I was highly frequent in the highest troponin ranges in a healthy reference population and showed no relationship with age or sex. The presence of macrotroponin I may impact clinical management in a considerable number of patients, but further investigation is required in clinical studies.

Abstract The Association for Diagnostics & Laboratory Medicine (ADLM) aims to improve health by providing education to laboratory scientists worldwide. Different regions of the world face unique challenges shaped by their national and regional contexts. However, the needs of clinical laboratories worldwide remain largely understudied. To address this gap, we conducted a comprehensive needs assessment survey among laboratory professionals in the Latin American region. The survey was distributed to over 2708 individuals across Latin American countries and yielded 148 responses. Most respondents were from urban areas (74%) and worked in private hospital laboratories (45%), with microbiology (25%) and chemistry (23%) identified as the most common specialties. Key findings include continuing education as the top challenge, identified by 59% of respondents, with a predominant preference for virtual learning formats (83%), though not exclusively; 50% also identified a preference for in-person learning. Other challenges, such as staff shortages, lack of equipment and funding, were selected by 30% to 36% of respondents, whereas regulatory oversight and quality management were less frequently identified as priorities. To contextualize the survey findings, we conducted interviews with laboratory professionals in the region. Common themes included resource and technology constraints, uneven implementation of quality standards, and the need for collaboration between government and professional organizations to bridge gaps in practice. This assessment highlights the need for targeted educational interventions to address the distinct challenges faced by Latin American laboratories. Addressing these gaps in continued education, fostering collaboration, and engaging stakeholders in the region offer a roadmap to strengthening laboratory services and health outcomes.

Abstract Background Identification of the microorganisms causing infection in children with central nervous system infection is important. Conventional cerebrospinal fluid (CSF) tests may provide limited pathogen detection. CSF metagenomic next-generation sequencing (mNGS) may provide broader pathogen detection in a single assay. Methods Results of CSF mNGS testing performed at Mayo Clinic on patients and nonpatients between January 2024 and June 2025 were retrospectively analyzed. The subcohort of children treated at Mayo Clinic was analyzed to assess test performance as compared with conventional CSF diagnostics and potential clinical impact. Results In total 134 patients (138 CSF mNGS tests) from 22 US states and 2 international sites were included. Overall positivity was 16% with viruses representing most (59%) detections. In the Mayo Clinic subcohort (n = 15), test positivity was 27%: organisms included single detections of Streptococcus mitis group and HIV type 1, as well as 2 detections of Epstein-Barr virus, all confirmed by conventional tests. Positive results were associated with CSF pleocytosis (P = .026). Higher yield was observed in participants whose care was overseen by pediatric infectious diseases (PID) specialists (P = .026) and when a specimen hold strategy was applied (P = .033). Most results (87%) did not alter antimicrobial therapy, with 2 negative results contributing to antimicrobial de-escalation. Conclusions CSF mNGS demonstrated higher diagnostic yield in patients whose specimens showed CSF pleocytosis and in those who had PID consultation. Diagnostic stewardship strategies were applied, including specimen hold approaches and PID consultation.